Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration SILICON VALLEY, Calif., (September 20, 2022) – Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...
SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held September 9-13, 2022, in Paris, France. Predicine’s liquid biopsy portfolio includes high performing assays that provide translational insights to aid in potential cancer therapeutic strategies....
SILICON VALLEY, Calif., Aug 09, 2022 / Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine. The PredicineCARETM cell free DNA (cfDNA) assay is a targeted Next-Generation Sequencing (NGS) assay for the detection of single nucleotide variants (SNVs), insertions and deletions (Indels), DNA re-arrangements (fusions)...
SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) — Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today a nationwide expansion of its COVID-19 testing solution through the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of Predicine’s SARS-CoV-2 RT-PCR test and self-collection kit....
Predicine Liquid Biopsy Outperforms Four other Leading ctDNA NGS Tests in a Study Led by Bristol Myers Squibb SILICON VALLEY, Calif., May 13, 2022 /PRNewswire/ — Predicine, Inc., a global molecular insights company, today announced the results of a new research study that demonstrated superior performance of the PredicineATLAS™ liquid biopsy next-generation sequencing (NGS) assay compared to four...
Predicine to Attend 2022 AACR Conference in New Orleans to Highlight the Launch of PredicineBEACON™, a Novel, Tissue-agnostic, Actionable Assay for Minimal Residual Disease (MRD) Detection and the Recent Publication of Several Studies in Genitourinary (GU) Cancers PredicineBEACON™ offers ultra-sensitive detection of disease recurrence and is compatible with blood, urine- and/or tissue specimens. Urine-based MRD has...
Predicine Expands Its Footprint in the Greater Chicago Area to Better Serve Their Patients by Increasing Daily Capacity and Faster Turnaround Time SCHAUMBURG, Ill., April 11, 2022 /PRNewswire/ — Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announces the grand opening of its Chicago lab in Schaumburg, IL on April 2, 2022. This lab...
Predicine to Present Six Studies, including the Demonstration of the Clinical Utility of Its PredicineBEACON™, a Tissue-agnostic MRD Liquid Biopsy Solution, in Genitourinary (GU) Cancers at 2022 ASCO-GU Annual Conference PredicineBEACON™ platform offers next-generation, tissue-agnostic MRD detection, leveraging blood, urine- and/or tissue-based comprehensive genomic profiling solutions in solid tumors including bladder, prostate, and renal tumors...
Predicine Appoints Clint Webb as New General Counsel to Support Its International Expansion SILICON VALLEY, Calif., Jan. 19, 2022 /PRNewswire/ — Predicine, a global molecular insights company, announced today that it has appointed Clint Webb as its new General Counsel (GC). This is the most recent of several executive appointments aimed at supporting Predicine’s international expansion and further developing its industry-leading liquid...
Predicine Appoints Dr. Dennis Merkle as New Chief Executive Officer SILICON VALLEY, Calif., Jan. 4, 2022 /PRNewswire/ — Predicine, a global molecular insights company, announced today that it has appointed Dennis Merkle, PhD, MBA, as its new Chief Executive Officer (CEO) for Predicine Europe as well as its Global Head of Biopharma Business. Dr. Merkle moves into the...
